China-based biopharmaceutical firm BeiGene (BGNE) has received approval for its anti-PD-1 antibody tislelizumab from the China National Medical Products Administration (NMPA) for the …
Commercial-stage biotechnology company BeiGene Ltd. reported data on the combination of tislelizumab and sitravatinib, which is being evaluated for the treatment of solid …
Oppenheimer top analyst expects 2Q beat on August 22nd
